With a highly-scalable and enterprise-level system such as Genedata Expressionist for Genomic Profiling, we are enabling our customers to become leaders in the emerging fields of personalized medicine and molecular diagnostics
London, England (PRWEB) November 14, 2011
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Expressionist 7.0 for Genomic Profiling, which will be featured at the 3rd Annual Next Generation Sequencing Congress. The Congress showcases besides next generation sequencing (NGS) platforms and technologies some of the industry-leading computational tools for analyzing NGS data, including Genedata Expressionist for Genomic Profiling as the first-in-class enterprise-level NGS data processing and analysis solution. Version 7.0, which easily manages and analyzes massive amounts of NGS data, provides scalability with no limitation on experiment size or number of users. Genedata will demonstrate Genedata Expressionist 7.0 at Booth #9 and the system will be featured in the NGS Congress Solution Presentations (Nov 14 -15, Radisson Edwardian Hotel).
New Benchmarks in NGS Data Analysis
Genedata Expressionist 7.0 for Genomic Profiling sets new standards for NGS data analysis. In minutes instead of hours, the system simultaneously analyzes transcriptomics, copy number variation, variant, and DNA methylation data from a large number of cancer cell lines. It also features a flexible and interactive genomic browser that can visualize terabytes of data and provide real-time feedback at every processing step. Vendor- and technology-agnostic, the solution helps to maximize the value of high throughput NGS experiments in combinations such as:
- next generation sequencing with microarray data;
- transcriptomics data with DNA methylation data;
- small RNA data with gene expression data; and
- copy number variation data with Single Nucleotide Polymorphism (SNP) data.
“The integrative analysis of NGS data is key to advancing our understanding of biological systems and diseases and will be a cornerstone for successful biomarker discovery projects. With a highly-scalable and enterprise-level system such as Genedata Expressionist for Genomic Profiling, we are enabling our customers to become leaders in the emerging fields of personalized medicine and molecular diagnostics,” said Dr. Othmar Pfannes, CEO of Genedata. “By giving researchers the capabilities to process and analyze massive amounts of genomic data, Genedata Expressionist is effectively accelerating the pace and improving the efficiency of NGS-based science.”
On November 15 at the NGS Congress, Genedata will present “Next Generation Software for Next Generation Sequencing Data.” To schedule a Genedata Expressionist briefing and demonstration, email expressionist(at)genedata(dot)com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany, and the US. http://www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.